Grown Rogue International (GRUSF) Other Non Operating Income (2010 - 2026)
Grown Rogue International's (GRUSF) quarterly Other Non Operating Income came in at $165268.0 in Q1 2026, down 79.26% year-on-year from $796956.0 in Q1 2025, and up 100.0% quarter-over-quarter from -$5714.4 billion in Q4 2025.
Grown Rogue International (GRUSF) Other Non Operating Income (2010 - 2026) Analysis & Trends
Grown Rogue International's Other Non Operating Income history runs 16 years deep, the most recent figure standing at $165268.0 for Q1 2026.
- On a quarterly basis, Other Non Operating Income fell 79.26% year-over-year to $165268.0 in Q1 2026; TTM through Mar 2026 was -$5738.6 billion, a 143.45% decrease from a year earlier, with the FY2025 full-year figure at $240115.0, down 98.12% from the prior year.
- Other Non Operating Income climbed to $165268.0 in Q1 2026 per GRUSF's latest filing, from -$5714.4 billion in the prior quarter.
- Across five years, Other Non Operating Income topped out at $13584.8 billion in Q4 2024 and bottomed at -$5714.4 billion in Q4 2025.
- The 4-year median for Other Non Operating Income is -$103176.0 (2023), against an average of $533.4 billion.
- Across the five-year window, Other Non Operating Income surged 4031322761.13% in 2024 and slumped 142.06% in 2025, its largest moves.
- Year by year, Other Non Operating Income stood at $336981.0 in 2023, then jumped by 4031322761.13% to $13584.8 billion in 2024, then slumped by 142.06% to -$5714.4 billion in 2025, then soared by 100.0% to $165268.0 in 2026.
- Per Business Quant, the three latest GRUSF Other Non Operating Income figures stand at $165268.0 (Q1 2026), -$5714.4 billion (Q4 2025), and -$24.2 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Grown Rogue International | 99.32 Mn | 85.61 Mn | 3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 165,268.00 |
| Dec 31, 2025 | -5,714.40 Bn |
| Sep 30, 2025 | -24.24 Bn |
| Jun 30, 2025 | 2.90 Mn |
| Mar 31, 2025 | 796,956.00 |
| Dec 31, 2024 | 13,584.79 Bn |
| Sep 30, 2024 | -378.59 Bn |
| Jun 30, 2024 | -7.55 Mn |
| Mar 31, 2024 | -5.66 Mn |
| Dec 31, 2023 | 336,981.00 |
| Oct 31, 2023 | 217,713.00 |
| Jul 31, 2023 | -1.18 Mn |
| Apr 30, 2023 | -270,712.00 |
| Jan 31, 2023 | 64,360.00 |
| Oct 31, 2021 | 1.13 Mn |
| Jul 31, 2021 | 53.00 |
| Apr 30, 2021 | 114,997.00 |
| Jan 31, 2021 | 319,627.00 |
| Oct 31, 2020 | -158,056.00 |
| Jul 31, 2020 | 23,939.00 |